When did Castle Biosciences report Q4 2024 earnings?

Castle Biosciences (CSTL) reported Q4 2024 earnings on February 27, 2025 after market close.

What were Castle Biosciences's Q4 2024 revenue and EPS?

Castle Biosciences reported revenue of $86.3M and eps of $0.32 for Q4 2024.

Did Castle Biosciences beat estimates in Q4 2024?

Revenue beat the consensus estimate of $83.9M by $2.4M. EPS beat the consensus estimate of $-0.04 by $0.36.

Where can I find Castle Biosciences's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001447362-25-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.

Castle Biosciences CSTL Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$86.3MBeat by $2.4M

EPS$0.32Beat by $0.36

Revenue estimate$83.9M

EPS estimate-$0.04

Next report

Jul 30, 2026 (Today)

Revenue estimate$86.2M

EPS estimate-$0.44

Financials

Q4 2024

Income statement

See full

Revenue$86.3M+30.5%

Gross profit$70.1M+30.6%

Operating income$4.1M+172%

Net income$9.6M+472%

EPS (diluted)$0.32+456%

Balance sheet

See full

Cash & equivalents$119.7M+21.1%

Total debt$26.4M+71.7%

Total equity$455.8M+16.5%

Total assets$531.2M+17.2%

Cash flow

See full

Operating cash flow$24.4M—

CapEx$7.6M+99.5%

Free cash flow$16.8M—

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$746.39M+28.5%

Enterprise value$653.13M+31.3%

P/E40.9×—

P/S2.2×-0.4×

Profitability

See full

Gross margin81.9%+2.3pp

Operating margin2.6%+1.4pp

Net margin5.5%+3.0pp

FCF margin11%—

Returns & leverage

See full

Return on equity4.3%+2.4pp

Debt / equity0.1×0.0×

Current ratio7.3×+1.1×

Segments

By product

See full

Dermatologic$63.8M+19.7%

Non-Dermatologic$22.5M+75.5%

By segment

See full

Reportable Segment$86.3M+57.1%

Versus estimates

Revenue

Q1 2026$84.2MBeat by $5.0M Q4 2025$87.0MBeat by $7.1M Q3 2025$83.0MBeat by $2.7M Q2 2025$86.2MBeat by $18.2M Q1 2025$88.0MBeat by $16.2M

Q4 2024$86.3MBeat by $2.4M

Diluted EPS

Q1 2026-$0.49In line Q4 2025-$0.08Beat by $0.15 Q3 2025-$0.02Beat by $0.32 Q2 2025$0.15Beat by $0.66 Q1 2025-$0.20Miss by $0.12

Q4 2024$0.32Beat by $0.36

Ask the moment Castle Biosciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Castle Biosciences report Q4 2024 earnings?: Castle Biosciences (CSTL) reported Q4 2024 earnings on February 27, 2025 after market close.
What were Castle Biosciences's Q4 2024 revenue and EPS?: Castle Biosciences reported revenue of $86.3M and eps of $0.32 for Q4 2024.
Did Castle Biosciences beat estimates in Q4 2024?: Revenue beat the consensus estimate of $83.9M by $2.4M. EPS beat the consensus estimate of $-0.04 by $0.36.
Where can I find Castle Biosciences's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001447362-25-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.